What is the standard dosing protocol for Semaglutide (GLP-1)?

Conventional Semaglutide (GLP-1) dosing is 0.25-2.4 mg weekly (titrated) 1x weekly subq via subq/oral (rybelsus, 7-14 mg daily). For female hormonal and cyclical use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

What is the regulatory status of Semaglutide (GLP-1)?

Semaglutide (GLP-1) regulatory status: Approved (Ozempic 2017, Wegovy 2021) in the United States; WADA status not on prohibited list; research level extensive phase iii and post-marketing. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For female hormonal and cyclical use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

What should I look for in Semaglutide (GLP-1) sourcing and quality?

Acceptable Semaglutide (GLP-1) certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching ~4114 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

What is the evidence base for Semaglutide (GLP-1)?

Semaglutide (GLP-1)'s evidence base sits at extensive phase iii and post-marketing. The references on this page summarise 3 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The female physiology interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

How long until I see results from Semaglutide (GLP-1)?

Acute effects from Semaglutide (GLP-1) appear within the first week for downstream physiological adaptation. female hormonal and cyclical endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

Home/ Compounds/ Semaglutide (GLP-1)

Semaglutide (GLP-1)

Women's Health

Cycle-aware, fertility-aware, perimenopause-aware: Semaglutide (GLP-1) is evaluated by women's-health clinicians on multiple axes. Selective GLP-1 receptor agonist Augments glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts centrally in the arcuate nucleus to suppress appetite. Fatty acid sidechain and substitutions extend half-life to ~7 days.. The compound's glp-1 receptor agonist pharmacology produces measurable effects on the systems women's-health practice cares about — cycle regularity, mood, bone density, cardiovascular tone, and the perimenopausal transition. Each is examined in the sections below.

Female Physiology Applications

Cycle SupportFertilityBone DensityPCOS SupportCardiovascular (Female)

Key Takeaways

Female-physiology lens: Semaglutide (GLP-1) response varies across follicular and luteal phases for premenopausal users; integrates with HRT in perimenopause and postmenopause.
Mechanism: Selective GLP-1 receptor agonist.
Female monitoring: cycle-day-appropriate estradiol, progesterone, FSH, LH, prolactin, TSH, bone markers; pregnancy contraindication is default.
Female dose: 0.25-2.4 mg weekly (titrated) 1x weekly subq via subq/oral (rybelsus, 7-14 mg daily); cycle-phase tracking for 1-2 cycles.
Female-physiology stack partners: Oxytocin, Kisspeptin, GHK-Cu.

Female Physiology Mechanism

Selective GLP-1 receptor agonist. Augments glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts centrally in the arcuate nucleus to suppress appetite. Fatty acid sidechain and substitutions extend half-life to ~7 days. For women's-health applications, the mechanism is evaluated against cyclical context, fertility implications, bone remodelling, and cardiovascular tone. Semaglutide (GLP-1)'s contribution to each varies; the subsections below work through these in turn.

Perimenopause and menopause integration

For women in the perimenopausal or post-menopausal window, Semaglutide (GLP-1) is most effective when integrated with the broader hormonal picture — HRT (estrogen, progesterone, sometimes testosterone), bone-density support, and cardiometabolic monitoring. Many compounds in this category produce stronger effects in this window precisely because the surrounding hormonal landscape is changing.

Bone density and cardiovascular signalling

Two areas where female physiology diverges sharply post-menopause are bone remodelling and cardiovascular tone. Semaglutide (GLP-1)'s effect on these systems is one of the underweighted but practically important considerations for women using peptides through the menopausal transition. Bone-marker labs (CTX, P1NP) and cardiovascular indices (lipids, blood pressure, hsCRP) provide a tractable monitoring framework.

Fertility and reproductive considerations

Semaglutide (GLP-1)'s effect on fertility-relevant endpoints — ovulation, ovarian reserve markers, uterine receptivity, lactation — deserves explicit consideration for women in the reproductive window. Most well-studied compounds have minimal direct effect on reproductive endpoints at therapeutic doses, but pregnancy and active conception remain explicit contraindications for most non-approved peptides.

Female Physiology Applications

Libido (Female)

For libido (female) in female users, Semaglutide (GLP-1) is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.

Body Composition (Female)

Body Composition (Female) is one of the dimensions on which women track Semaglutide (GLP-1) response. Effect size depends on baseline hormonal status and on integration with HRT or contraception. Tracking by cycle phase for the first 1–2 cycles informs subsequent scheduling.

Cycle Support

In the perimenopausal window, Semaglutide (GLP-1) for cycle support produces stronger response than in pre-menopausal users with intact cyclical hormone background, reflecting the changed receptor landscape rather than any change in the compound's pharmacology.

Cognitive (Cycle/Menopause)

For cognitive (cycle/menopause) in female users, Semaglutide (GLP-1) is best-integrated with the broader hormonal picture — cycle-aware dosing for premenopausal women and continuous dosing typically more appropriate for perimenopausal and post-menopausal users. Cycle response varies meaningfully by phase.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	0.25-2.4 mg weekly (titrated)	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	1.25-2.4 mg weekly (titrated)	4–6 weeks initial cycle
Women's Health focus	SubQ	0.25-2.4 mg weekly (titrated)	1x weekly SubQ
Maintenance phase	SubQ	1.25-2.4 mg weekly (titrated)	Ongoing with periodic pauses

Dose timing for Semaglutide (GLP-1) is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Semaglutide (GLP-1) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from women's-health clinicians.

Semaglutide (GLP-1) + Oxytocin: Activates oxytocin receptors (OXTR) peripherally (uterine smooth muscle, mammary alveoli) and centrally (amygdala, hypothalamus, ventral tegmentum). Pairs naturally with Semaglutide (GLP-1)'s mechanism in female physiology protocols.
Semaglutide (GLP-1) + Kisspeptin: Activates the KISS1R (GPR54) on GnRH neurons in the hypothalamus, triggering GnRH release. Pairs naturally with Semaglutide (GLP-1)'s mechanism in female physiology protocols.
Semaglutide (GLP-1) + GHK-Cu: GHK chelates copper(II) and acts as a transcriptional modulator: published microarray data show it influences over 4,000 human genes including resetting expression patterns toward younger cellular phenotypes. Pairs naturally with Semaglutide (GLP-1)'s mechanism in female physiology protocols.
Semaglutide (GLP-1) + Epithalon: Identified by Khavinson in St. Pairs naturally with Semaglutide (GLP-1)'s mechanism in female physiology protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Approved (Ozempic 2017, Wegovy 2021) Research: Extensive Phase III and post-marketing

GI events (nausea, vomiting, constipation) most common. Pancreatitis caution. Avoid in personal/family history of medullary thyroid carcinoma or MEN-2. Pregnancy: contraindicated.

Lens-specific safety considerations for female physiology use of Semaglutide (GLP-1): GI events (nausea, vomiting, constipation) most common. Pancreatitis caution. Avoid in personal/family history of medullary thyroid carcinoma or MEN-2. Pregnancy: contraindicated. Additional female physiology monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

STEP 1 — Once-weekly semaglutide in adults with overweight or obesity

PMID 33567185

Supporting

STEP 2 — Semaglutide in type 2 diabetes and obesity

PMID 33567186

Semaglutide (GLP-1) vs Related Peptides

Compound	Profile	Onset	Best For
Semaglutide (GLP-1)	GLP-1 receptor agonist	~7 days	Women's Health
Oxytocin	Posterior pituitary nonapeptide	~1-6 min plasma; CNS longer	The 'bonding hormone' — a posterior pituitary nonapeptide with effects on uterine contraction, lactation, and a wide range of social and sexual behaviour via central oxytocin receptors
Kisspeptin	Hypothalamic upstream regulator of GnRH	~28 min IV	The upstream master regulator of GnRH neurons — driving the entire HPG axis from above
PT-141	Melanocortin receptor agonist	~2-3 hr	An MC3R/MC4R agonist derived from Melanotan II — FDA-approved as bremelanotide for HSDD in premenopausal women

Frequently Asked Questions

Best monitoring labs for female users?

Baseline panel: estradiol (cycle-day-appropriate), progesterone, FSH, LH, prolactin, TSH free T3 free T4, fasting glucose, HbA1c, lipids, CBC, CMP, hsCRP, vitamin D, ferritin. Follow-up at 6–8 weeks. For perimenopausal users add bone markers (CTX, P1NP) and cardiovascular indices.

Will Semaglutide (GLP-1) affect contraceptive efficacy?

For most peptide compounds, contraceptive efficacy is not significantly affected. Compounds directly modulating the HPG axis (kisspeptin, gonadorelin) are exceptions and warrant alternative or additional contraceptive measures during use. Semaglutide (GLP-1)'s specific interaction follows its mechanism.

Can I use Semaglutide (GLP-1) during pregnancy or while trying to conceive?

Most peptide therapeutics, including Semaglutide (GLP-1), do not have safety data supporting use during pregnancy or active conception. The default position is to discontinue at least 2–3 cycles before planned conception and to avoid throughout pregnancy and lactation unless specifically approved by a physician familiar with the indication.

Is Semaglutide (GLP-1) appropriate during perimenopause?

Yes, and many women report stronger response in the perimenopausal window than at younger ages. The interaction with HRT — estrogen, progesterone, sometimes testosterone — is generally additive rather than competitive. Bone density, cardiovascular, and metabolic monitoring continues to apply.

How does Semaglutide (GLP-1)'s half-life affect dosing?

Semaglutide (GLP-1) has a plasma half-life of ~7 days, which is long enough that single-weekly dosing is operationally viable. The receptor occupancy curve under 1x weekly subq dosing at 0.25-2.4 mg weekly (titrated) per dose explains the typical onset timeline for female hormonal and cyclical endpoints.

What are the safety considerations for Semaglutide (GLP-1)?

GI events (nausea, vomiting, constipation) most common. Pancreatitis caution. Avoid in personal/family history of medullary thyroid carcinoma or MEN-2. Pregnancy: contraindicated. For female hormonal and cyclical use, additional considerations: baseline labs appropriate to the targeted system, mid-cycle re-check at 4–6 weeks, and end-of-cycle full re-evaluation. Semaglutide (GLP-1)'s ~7 days pharmacokinetic profile and subq/oral (rybelsus, 7-14 mg daily) administration route influence the side-effect profile in predictable ways.

Clinical Protocol

Start a Semaglutide (GLP-1) Protocol

Alukard provides physician-supervised women's health protocols with GMP-certified Semaglutide (GLP-1) and Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get Protocol

Quick Facts

Molecular weight: ~4114 Da
Sequence length: 31 aa
Half-life: ~7 days
WADA: Not on prohibited list
FDA: Approved (Ozempic 2017, Wegovy 2021)
Research: Extensive Phase III and post-marketing

Stack Partners

Oxytocin

Kisspeptin

GHK-Cu

Epithalon

PT-141

Research Note

All female physiology applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Semaglutide (GLP-1) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised women's health protocols

Start Your Female Physiology Protocol for Semaglutide (GLP-1)

Alukard provides physician-supervised women's health protocols with Cycle-aware dosing, comprehensive hormone panels, and GMP-certified compounds.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised